...
首页> 外文期刊>Attention deficit and hyperactivity disorders >Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review
【24h】

Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review

机译:注意缺陷多动障碍的注意力不集中和联合亚型中的阿托西汀反应:回顾性图表回顾

获取原文
获取原文并翻译 | 示例
           

摘要

The DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, 1994, American Psychiatric Association) describes attention deficit hyperactivity disorder (ADHD) as a heterogeneous disorder; providing diagnostic criteria for three subtypes: hyperactive/impulsive (ADHD/HI), inattentive (ADHD/I), and combined type (ADHD/C). Differences among the subtypes are well defined, but there may be also differences in terms of treatment responses. The aim of this study is to assess the responses of ADHD/I and ADHD/C to atomoxetine treatment. The medical records of the January-June 2012 term, first time referrals to outpatient clinic, were reviewed, and 37 ADHD diagnosed primary school age children (18 ADHD/I, 19 ADHD/C) that were treated with atomoxetine were determined. Thirty-five of them who completed 8 weeks of treatment duration were recruited for the study. The children with an ADHD medication use history in 2 months time prior to onset of treatment and/or the children receiving additional psychopharmacologic treatment to atomoxetine were excluded. Baseline and eighth week assessment, records were evaluated. Efficacy assessments included Turgay DSM-IV ADHD Screening and Rating Scale parent and teacher forms (T-DSM-IV) and Clinical Global Impression Scale-Severity and Improvement sub-scales. Safety assessments included laboratory and body weight assessments, ECG, heart rate, and blood pressure evaluations (baseline and eighth week) along a scale filled by the parents at the eighth week to review side effects. Atomoxetine was found to be effective in both ADHD/I and ADHD/C groups. Atomoxetine also decreased the opposition defiance subscale scores of T-DSM-IV (both parent and teacher forms), whereas it was not found to make statistically significant difference in the conduct disorder subscale scores. Mean difference in 8-week time in T-DSM-IV hyperactivity subscale and total scores of parent and teacher forms; inattention subscale scores of only parent forms and the CGI- severity subscale scores; differed significantly among the ADHD/I and ADHD/C groups; that ADHD/C types responded better to medication. Results of this study revealed that atomoxetine is effective both in ADHD/I and ADHD/C subtypes. ADHD/C types may be responding better to atomoxetine treatment than the ADHD/I subtypes.
机译:DSM-IV-TR(《精神障碍诊断和统计手册》,1994年,美国精神病学协会)将注意力缺陷多动障碍(ADHD)描述为一种异质性疾病。提供三种亚型的诊断标准:过度活跃/冲动(ADHD / HI),注意力不集中(ADHD / I)和组合型(ADHD / C)。亚型之间的差异已明确定义,但在治疗反应方面也可能存在差异。本研究的目的是评估ADHD / I和ADHD / C对阿莫西汀治疗的反应。回顾了2012年1月至6月学期的医疗记录,首次转诊至门诊,并确定了接受阿托莫西汀治疗的37位经ADHD诊断的小学年龄儿童(18位ADHD / I,19位ADHD / C)。招募了其中35名完成了8周治疗时间的患者用于研究。在治疗开始前2个月内有ADHD药物使用史的儿童和/或接受对阿托西汀进行额外心理药物治疗的儿童被排除在外。基线和第八周评估,评估记录。疗效评估包括Turgay DSM-IV ADHD筛查和评定量表父母和教师表格(T-DSM-IV)和临床总体印象量表-严重程度和改善量表。安全评估包括实验室和体重评估,心电图,心率和血压评估(基线和第八周),该评估由父母在第八周填写以评估副作用。发现阿托西汀在ADHD / I和ADHD / C组中均有效。 Atomoxetine还降低了T-DSM-IV(父母和教师形式)的对立抗逆性次级量表分数,而在行为障碍次级量表分数上没有发现统计学上的显着差异。 T-DSM-IV多动症分量表中8周时间的平均差异以及家长和教师形式的总分;仅父母形式的注意力不集中量表分数和CGI严重性分量表分数; ADHD / I和ADHD / C组之间存在显着差异; ADHD / C类型对药物反应更好。这项研究的结果表明,阿托西汀在ADHD / I和ADHD / C亚型中均有效。与ADHD / I亚型相比,ADHD / C型对阿莫西汀治疗的反应可能更好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号